Schering’s sugammadex gets panel review
Schering-Plough's selective relaxant binding agent Bridion (sugammadex) will be reviewed by FDA's Anesthesia and Life Support Drugs Advisory Committee on March 11. The drug is under priority review for reversing neuromuscular blockade by certain muscle relaxants used in general anesthesia, and FDA action is expected in the second quarter. This is the first open new product review for the Anesthesia panel since 1999...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.